|Mr. Michael S. Weiss||Exec. Chairman, CEO & Pres||N/A||N/A||1966|
|Mr. Sean A. Power CPA||CFO, Corp. Sec. & Treasurer||435.84k||N/A||1982|
|Jenna Bosco||VP of Investor Relations & Sr. VP of Corp. Communications||N/A||N/A||N/A|
|Mr. Adam Waldman||Chief Commercial Officer||N/A||N/A||N/A|
TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the lead two therapies, such as Ublituximab and Umbralisib in pivotal trials for CLL, NHL, and MS. Its Ublituximab is a novel anti-CD20 monoclonal antibody that has been glycoengineered for enhanced potency over first generation antibodies; and Umbralisib is an oral, once daily inhibitor of PI3K delta. The company also develops TG-1501, an anti-PD-L1 monoclonal antibody; TG-1701, an oral Bruton's Tyrosine Kinase; and TG-1801, an anti-CD47/CD19 bispecific antibody. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
TG Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 4; Compensation: 10.